Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Michael Kennelly, Lonny Green, Nancy Alvandi, Salim Wehbe, John Joseph Smith$suffix/text()$suffix/text(), Scott MacDiarmid, Jeffrey Mangel, Marc Schwartz, Tamer Aboushwareb & Brian Murray. (2018) Clean intermittent catheterization rates after initial and subsequent treatments with onabotulinumtoxinA for non-neurogenic overactive bladder in real-world clinical settings. Current Medical Research and Opinion 34:10, pages 1771-1776.
Read now
Read now
Zalmai Hakimi, Jameel Nazir, Charles McCrea, Malin Berling, Francis Fatoye, Barbara Ramos & Adrian Wagg. (2017) Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada. Journal of Medical Economics 20:6, pages 614-622.
Read now
Read now
Adrian Wagg. (2016) Persistence with medication and overactive bladder: an ongoing challenge. Expert Review of Pharmacoeconomics & Outcomes Research 16:4, pages 475-481.
Read now
Read now
Articles from other publishers (14)
Tugrul Cagri Akman, Yucel Kadioglu, Onur Senol & Beyzagul Erkayman. (2022) Metabolomics approach: Interpretation of changes in rat plasma metabolites after solifenacin treatment. Brazilian Journal of Pharmaceutical Sciences 58.
Crossref
Crossref
Mahmood Ali, Sarah Grogan, Sue Powell, Leanne Staniford, Jameel Nazir, Margarita Landeira, Patrick J. O. Covernton, Ashley Jaggi, Francis Fatoye & Maxine Holt. (2019) Qualitative Analysis of Factors Influencing Patient Persistence and Adherence to Prescribed Overactive Bladder Medication in UK Primary Care. Advances in Therapy 36:11, pages 3110-3122.
Crossref
Crossref
Gillian Yeowell, Philip Smith, Jameel Nazir, Zalmai Hakimi, Emad Siddiqui & Francis Fatoye. (2018) Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open 8:11, pages e021889.
Crossref
Crossref
Henry J. Woodford. (2018) Anticholinergic Drugs for Overactive Bladder in Frail Older Patients: The Case Against. Drugs & Aging 35:9, pages 773-776.
Crossref
Crossref
Hui-Yun Gu, Ju-Kun Song, Wen-Jun Zhang, Jin Xie, Qi-Sheng Yao, Wen-Jing Zeng, Chao Zhang & Yu-Ming Niu. (2017) A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages. Oncotarget 8:52, pages 90338-90350.
Crossref
Crossref
Michael Kennelly, Roger Dmochowski, Heinrich Schulte-Baukloh, Karen Ethans, Giulio Del Popolo, Courtenay Moore, Brenda Jenkins, Steven Guard, Yan Zheng & Gilles Karsenty. (2017) Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study. Neurourology and Urodynamics 36:2, pages 368-375.
Crossref
Crossref
Kirill Vladimirovich Kosilov, Sergay Alexandrovich Loparev, Irina Gennadyevna Kuzina, Olga Viktorovna Shakirova, Natalia Sergeevna Zhuravskaya & Alexandra Lobodenko. (2016) Factors of trospium treatment compliance among unemployed older persons. Journal of Clinical Gerontology and Geriatrics 7:4, pages 124-130.
Crossref
Crossref
Victor W. Nitti, David Ginsberg, Karl-Dietrich Sievert, David Sussman, Sidney Radomski, Peter Sand, Dirk De Ridder, Brenda Jenkins, Andrew Magyar, Christopher Chapple, Veronique Keppenne, Stijn Schapman, Dirk DeRidder, Karel Everaert, Bart Kimpe, Thierry Quackels, Peter Vossaert, Jean-Jacques Wyndaele, Russell Egerdie, David Eiley, Sender Herschorn, Peter Pommerville, Sidney Radomski, Gary Steinhoff, Pavel Navr?til, Miloslav Sincl, Vladimir Student, Jaroslav Vseticka, Jiri Heracek, Vaclav Janda, Jan Mecl, Jan Schraml, Joachim Grosse, Elke Hessdoerfer, Ruth Kirschner-Hermanns, Karl-Dietrich Sievert, Stefan Carl, Albert Kaufmann, Hagen Loertzer, Ursula Peschers, Lucyna Grochala, Rafal Kmieciak, Piotr Radziszewski, Tomaz Rechberger, Zenona Jablonska, Salman Al-Shukri, Sergey Darenkov, Grigoriy Krivoborodov, George Uchvatkin, Oleg Apolikhin, Andrey Gorelov, Sergey Gorelov, Dmitry Pushkar, Oleg Teodorovich, Marcus Drake, Voula Granitsiotis, Malcolm Lucas, Christopher Chapple, Vikram Khullar, Paraskeve Granitsiotis, Matthew Parsons, Mark Speakman, Joseph Antoci, Corlis Archer-Goode, Stephen Auerbach, James Bailen, Teresa Beam, Jeffrey Becker, Yitzhak Berger, Robert Biester, Shawn Blick, Robert Bradford, Daniel Burzon, Christopher Chermansky, Kevin Cline, Craig Comiter, Roger Dmochowski, Mitchell Efros, Jonathan Fialkov, Sheldon Freedman, Franklin Gaylis, David Ginsberg, David Glazier, Evan Goldfischer, Angelo Gousse, Lonny Green, Jennifer Gruenefelder, Douglass Hale, Bernard Hertzman, Nancy Huff, Igor Dumbadze, Karny Jacoby, Mark Jalkut, Susan Kalota, Jed Kaminetsky, Richard Kane, Marshall Kaplan, Gary Karlin, Charles King, Wendy Leng, Dawn King-Menzner, Ira Klimberg, Carl Klutke, Alfred Kohan, Kent Krejci, Gary Leach, David Lipsitz, Jeffrey Lumerman, Scott MacDiarmid, Eric Margolis, Keegan Maxwell, Kurt McCammon, Gretchen Mitchell, Robert Moore, William Moseley, Myron I. Murdock, Steven Mutchnik, Victor Nitti, David Oselinsky, Gerald Park, Jill Peters-Gee, Paul Pettit, McKay Platt, David Pollifrone, Brian Roberts, Harvey Samowitz, Peter Sand, Patrick Shenot, Paul Siami, Steven Siegel, Garrick Simmons, Jeffrey Small, Craig Smith, Jeffrey Snyder, Jennifer Sobol, Jodi Michaels, Christopher Steidle, Douglas Tietjen, Anne Viselli, Thomas Williams & Rafael Wurzel. (2016) Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study. The Journal of Urology 196:3, pages 791-800.
Crossref
Crossref
Uduak U. Andy, Lily A. Arya, Ariana L. Smith, Kathleen J. Propert, Hillary R. Bogner, Kristen Colavita & Heidi S. Harvie. (2016) Is self-reported adherence associated with clinical outcomes in women treated with anticholinergic medication for overactive bladder?. Neurourology and Urodynamics 35:6, pages 738-742.
Crossref
Crossref
A. Sicras-Mainar, R. Navarro-Artieda, A. Ruiz-Torrej?n, M. S?ez-Zafra & G. Coll-de Tuero. (2016) Persistence and concomitant medication in patients with overactive bladder treated with antimuscarinic agents in primary care. An observational baseline study. Actas Urol?gicas Espa?olas (English Edition) 40:2, pages 96-101.
Crossref
Crossref
A. Sicras-Mainar, R. Navarro-Artieda, A. Ruiz-Torrej?n, M. S?ez-Zafra & G. Coll-de Tuero. (2016) Persistencia y medicaci?n concomitante en pacientes con vejiga hiperactiva tratados con antimuscar?nicos en atenci?n primaria: estudio de base observacional. Actas Urol?gicas Espa?olas 40:2, pages 96-101.
Crossref
Crossref
Karel Everaert, Jennifer Gruenenfelder, Heinrich Schulte-Baukloh, Russell B Egerdie, Kristin Khalaf, Manher Joshi, Quanhong Ni & David Sussman. (2015) Impact of onabotulinumtoxinA on quality of life and practical aspects of daily living: A pooled analysis of two randomized controlled trials. International Journal of Urology 22:12, pages 1131-1137.
Crossref
Crossref
K.‐D. Sievert, C. Chapple, S. Herschorn, M. Joshi, J. Zhou, C. Nardo & V. W. Nitti. (2014) OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder. International Journal of Clinical Practice 68:10, pages 1246-1256.
Crossref
Crossref
Jong Hyun Yun, Jae Heon Kim, Jae Ho Kim, Sang Wook Lee, Hee Jo Yang, Seung Whan Doo & Won Jae Yang. (2014) Can We Decide the Optimal Initial Treatment for Male Lower Urinary Tract Symptoms Patients with Overactive Bladder by the Most Bothersome Symptom? A Randomized, Prospective, Open-Label Study. Urologia Internationalis 93:3, pages 338-343.
Crossref
Crossref